NDA 200533 · Collegium Pharm INC
Nucynta Er
Tapentadol Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Aug 25, 2011
Approved uses
3
Original approval plus efficacy supplements
Registered trials
73
35 Phase 3, 1 recruiting
FAERS reports
33,575
30,074 serious, 20,764 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF TAPENTADOL EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of tapentadol extended-release tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death assess, each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of tapentadol extended-release tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of tapentadol extended-release tablets are essential. Instruct patients to swallow tapentadol extended-release tablets whole;...
What it is approved for
From the label in effect Feb 26, 2026.
Tapentadol extended-release tablets are indicated for the management of: Severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve tapentadol extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. tapentadol extended-release tablets are not indicated as an as-needed (prn) analgesic. Tapentadol extended-release tablet is an opioid agonist indicated for the management of: severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. ( 1 ) severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use ( 1 ) Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death...
Mechanism: Tapentadol is a centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from both of these properties.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 14, 2024 Supplement 29 · Efficacy · priority review LetterLabelMedication Guide
- Aug 28, 2012 Supplement 1 · Efficacy LabelLetter
- Aug 25, 2011 Original approval · Type 3 - New Dosage Form ReviewLabelOther
5 products under this application
- NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 200MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 100MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 250MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 150MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tapentadol" as an intervention, any sponsor and status, largest first.
- An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00487435 · 1,166 participants · Start Jun 2007 · Primary completion Jun 2009
Drug: Tapentadol (CG5503) Extended Release (ER) · For: Pain; Osteoarthritis; Low Back Pain
Sites: Birmingham, Alabama; Hoover, Alabama; Mobile, Alabama · 148 sites in all
- A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00361504 · 1,123 participants · Start Nov 2006 · Primary completion Jul 2008
Drug: Oxycodone CR; Tapentadol (CG5503) ER · For: Osteoarthritis, Hip; Osteoarthritis, Knee; Lower Back Pain and 1 more
Sites: Mesa, Arizona; Tucson, Arizona; Anaheim, California · 52 sites in all
- Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.Pivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT01725087 · 1,089 participants · Start Nov 2012 · Primary completion Jul 2014
Drug: Matching Placebo; Low Dose GRT6005 and 3 more · For: Low Back Pain
Sites: Senftenberg, Austria; Vienna, Austria; Brussels, Belgium · 79 sites in all
- Tapentadol (CG5503)Pivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00421928 · 1,030 participants · Start Jan 2007 · Primary completion Jul 2008
Drug: oxycodone; placebo and 1 more · For: Osteoarthritis, Knee; Pain
- A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the KneePivotal-lookingCompleted
Grünenthal GmbHIndustry
NCT00486811 · 990 participants · Start Jun 2007 · Primary completion Jul 2008
Drug: Tapentadol ER (100 to 250 mg twice daily); Matching Placebo (twice daily) and 1 more · For: Pain; Knee Osteoarthritis
Sites: Innsbruck, Austria; Mitterdorf, Austria; Salzburg, Austria · 100 sites in all
- A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00449176 · 981 participants · Start Feb 2007 · Primary completion May 2008
Drug: tapentadol (CG5503) ER; oxycodone CR and 1 more · For: Low Back Pain
- A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.Pivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00613938 · 901 participants · Start Feb 2008 · Primary completion Oct 2008
Drug: Tapentadol (CG5503); Tapentadol (CG5503) and 2 more · For: Arthralgia; Bunion; Hallux Valgus and 1 more
Sites: Glendale, California; Pasadena, Maryland; Austin, Texas · 7 sites in all
- A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00364546 · 877 participants · Start Jul 2006 · Primary completion Jun 2007
Drug: CG 5503;tapentadol · For: Osteoarthritis; Pain Intensity Assessment; Arthralgia and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death11,645
- toxicity to various agents9,959
- overdose5,890
- drug abuse1,553
- drug dependence1,073
- drug ineffective1,039
- drug withdrawal syndrome neonatal944
- pain767
- nausea735
- accidental overdose721
- fatigue457
- headache418
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 98 |
| 2010 | 155 |
| 2011 | 350 |
| 2012 | 418 |
| 2013 | 377 |
| 2014 | 364 |
| 2015 | 1,376 |
| 2016 | 1,060 |
| 2017 | 2,490 |
| 2018 | 21,688 |
| 2019 | 848 |
| 2020 | 729 |
| 2021 | 705 |
| 2022 | 593 |
| 2023 | 559 |
| 2024 | 706 |
| 2025 | 546 |
| 2026 | 510 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nucynta ER (Tapentadol HCl)
2024 spending
$47.7M
Beneficiaries
5,370
40,396 claims
Per beneficiary
$8,890
$20.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $65,282,808 |
| 2021 | $63,697,831 |
| 2022 | $66,832,483 |
| 2023 | $53,178,879 |
| 2024 | $47,741,763 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review.
D'Souza RS, Barman R, Joseph A, et al. · Curr Pain Headache Rep 2022 · Systematic Review
- Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ, Wee B, Derry S, et al. · Cochrane Database Syst Rev 2017 · Research Support, Non-U.S. Gov't, Systematic Review
- Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.
Roulet L, Rollason V, Desmeules J, et al. · Drugs 2021 · Systematic Review
- Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial.
Sandhu HK, Booth K, Furlan AD, et al. · JAMA 2023 · Multicenter Study, Randomized Controlled Trial
- Tapentadol and oxycodone reduce cingulate glutamate in healthy volunteers.
Hansen TM, Frøkjaer JB, Mark EB, et al. · Br J Clin Pharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research.
Gressler LE, Hammond DA, Painter JT · J Pain Palliat Care Pharmacother 2017 · Systematic Review
Sponsor: Collegium Pharm INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.